Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 18/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1674160 | 0.92 | PTK2 (0.51) | PTK2JAK2BRD4 | |
| SCHEMBL29522986 | 0.92 | PTK2 (0.51) | PTK2JAK2BRD4 | |
| SCHEMBL1674290 | 0.85 | PTK2 (0.61) | PTK2KDR | |
| SCHEMBL14853188 | 0.79 | PTK2 (0.55) | PTK2JAK2BRD4 | |
| SCHEMBL17461677 | 0.77 | PTK2 (0.55) | PTK2JAK2BRD4 | |
| SCHEMBL17461682 | 0.76 | PTK2 (0.53) | PTK2JAK2BRD4 | |
| SCHEMBL1674333 | 0.76 | PTK2 (0.60) | PTK2JAK2BRD4 | |
| SCHEMBL29523379 | 0.76 | PTK2 (0.60) | PTK2JAK2BRD4 | |
| SCHEMBL1674084 | 0.75 | PTK2 (0.67) | PTK2JAK2BRD4 | |
| SCHEMBL1674300 | 0.73 | PTK2 (0.62) | PTK2JAK2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744831-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2023-09-05 | — | — | US | claimed |
| US-11065254-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2021-07-20 | — | — | US | claimed |
| US-20200206229-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2020-07-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744831-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | PTK2 2303/4885JAK2 4/4885BRD4 758/4885 |
| US-20200206229-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | PTK2 1835/4885JAK2 4/4885BRD4 585/4885 |
| US-11065254-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | PTK2 1835/4885JAK2 4/4885BRD4 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.